McCormick Place, Chicago, IL, USA
Innate Pharma will present a poster : “A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients with various hematologic or solid malignancies”
- Session Name: Poster Session: Developmental Therapeutics—Immunotherapy
- Date: Saturday, May 30, 2015
- Presentation time: 8:00 AM - 11:30 AM
| iph_poster_asco2015.pdf | 636.4 KB |
Date